ARTICLES BY LOUIS

• Beyond (And Better Than) mRNA: T Cell Vaccines

  2/1/2024

  During an extraordinary discussion with a historic biotech entrepreneur, he matter-of-factly interjects, “We’re leaving mRNA vaccines in the dust and moving onto a different approach to vaccines.” That ‘dust-generating’ approach is a proprietary T cell-based platform. And it has COVID and many other implications.

• Creating T Cell Vaccines In The Sands

  1/25/2024

  Like others, Saudi Arabia has been dependent on vaccines supply from abroad. That’s about to change. According to the CEO of Emergex, the Saudis intend to produce a new generation of vaccines – predominantly based on "T cell priming, the next step beyond mRNA vaccines.”

• Vaccine Manufacture From The U.K. to Brazil And Saudi Arabia

  1/22/2024

  Why is Professor Thomas Rademacher’s U.K-based vaccine-creating biotech so important that Saudi Arabia has based the establishment of the Kingdom’s first vaccine manufacturing facility on the company? The narrative starts in Brazil.

• Reinventing The Classic Pharma Campus

  1/15/2024

  Perhaps your company is located on, or considering expanding to, a biopharma or life-sciences campus. Ever wonder how these “campuses” (or “parks”) materialize? Jason Benson of JLL Life Sciences Real Estate Solutions explains to chief editor Louis Garguilo.

• Technical Talent Tailing Off At CDMOs?

  1/11/2024

  “Having been outsourcing to CDMOs for 20 years in the small-molecule space, I see a distinct difference in technical performance compared to my mid-2000s CDMOs," says an executive. What's going on here?

• Development And Commercial: 2 Supply Chains For An Ideal Future

  1/5/2024

  How do you transition a supply chain utilized for your development stages to a robust commercial supply chain? Thierry Bilbault knows how. He does done it before, and is at it again. He shares his strategies and secrets.

• 2024: An Outsourcing Future of Information Sharing

  1/3/2024

  I'm a big believer in open-source information as much as possible,” says Nana Collett. “Companies need proprietary information, but I'm a bit radical this way. I believe that as an ecosystem, we're going to get stronger if we can find our way to more data-sharing.” 

• Oligonucleotides Outsourcing In 2024

  12/26/2023

  2023, among other potential designations, was the year of oligonucleotides. Accordingly, here’s a question I raised with professionals throughout the year: How do you successfully outsource development and manufacture of an oligo program?

• Will 2024 Unlock Options Enabling Our Technologies

  12/20/2023

  Our Advisory Board members describe their outsourcing experiences during 2023, and offer us ideas and questions on how to make 2004 a better environment, specifically for all our advancing platforms.

• How To ID The Best CDMOs

  12/13/2023

  It takes a certain, trained perspicuity to identify the CDMO right for you. If you are a small biotech, says CEO Matthias Schroff, you most likely will not have the weight to ensure an external partner’s “real focus on producing for you.” Here's what he recommends.